Gamgee
Scalable Personalised Cancer Treatment
About Gamgee
Gamgee began with Rosie, founder Paul Conyngham’s dog. After surgery, chemotherapy and immunotherapy failed, Rosie was given months to live. Paul used AI and genomic analysis to identify targets in her tumour, then worked with scientists at UNSW to produce what is believed to be the first fully computationally designed mRNA cancer vaccine delivered to a dog. Following treatment, several tumours shrank significantly and her quality of life improved Gamgee is building an end to end platform for personalised mRNA cancer vaccines for dogs. We sequence a dog’s tumour and healthy DNA, identify mutations unique to its cancer, and design a vaccine that teaches the immune system what to attack. We manage the entire process- from vet intake and tissue collection through genomic analysis, vaccine production, treatment and response monitoring We are now turning that one off effort into a repeatable clinical system. Gamgee is running clinical trials in Australia, working with vets, oncologists and specialised laboratories, and accepting cases globally. Our goal is to make personalised cancer treatment accessible to every dog that needs it- and use each case to improve the treatment for the next
Founder
Paul Conyngham
Founder
Founder at Gamgee Technologies (YC S26), building personalised mRNA cancer vaccines. Gamgee grew out of my work using AI and genomics to help my dog Rosie fight cancer. Previously co-founded Core Intelligence, building applied AI systems across startups and enterprise, and helped grow Australia’s AI community through DSAI. Background in ML, data science and electrical and computer systems engineering